Iqbal J, Minhajuddin M, Beg Z H
Anatomy & Cell Biology, Box #5, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY-11203, USA.
Eur J Cancer Prev. 2004 Dec;13(6):515-20. doi: 10.1097/00008469-200412000-00009.
The anticancer efficacy of tocotrienol-rich fraction (TRF) was evaluated during diethylnitrosamine (DEN)/2-acetylaminofluorene (AAF)-induced hepatocarcinogenesis in male Sprague-Dawley rats. TRF treatment was carried out for 6 months, and was started 2 weeks before initiation phase of hepatocarcinogenesis. Morphological examination of the livers from DEN/AAF rats showed numerous off-white patches and few small nodules, which were significantly reduced by TRF treatment. Cytotoxic damage by DEN/AAF was estimated by alkaline phosphatase (ALP) release into the plasma from the cell membranes. DEN/AAF caused a twofold increase in the activity of ALP in plasma as compared with normal control rats, and this increase was prevented significantly by TRF treatment. We observed an increase of 79% in liver ALP activity in DEN/AAF rats, which was further increased by another 48% after the administration of TRF. Hepatic activity of glutathione S-transferase (GST) was also increased (3.5-fold) during the induction of hepatic carcinogenesis. Lipid peroxidation and low-density lipoprotein (LDL) oxidation increased threefold following initiation by DEN/AAF as compared with normal control rats. However, TRF treatment to DEN/AAF-treated rats substantially decreased (62-66%) the above parameters and thus limited the action of DEN/AAF. We conclude that long-term intake of TRF could reduce cancer risk by preventing hepatic lipid peroxidation and protein oxidation damage due to its antioxidant actions.
在雄性斯普拉格-道利大鼠二乙基亚硝胺(DEN)/2-乙酰氨基芴(AAF)诱导的肝癌发生过程中,评估了富含生育三烯酚的组分(TRF)的抗癌功效。TRF治疗持续6个月,在肝癌发生起始阶段前2周开始。对DEN/AAF大鼠肝脏的形态学检查显示有许多灰白色斑块和少量小结节,TRF治疗使其显著减少。通过碱性磷酸酶(ALP)从细胞膜释放到血浆中来评估DEN/AAF造成的细胞毒性损伤。与正常对照大鼠相比,DEN/AAF使血浆中ALP活性增加了两倍,而TRF治疗显著阻止了这种增加。我们观察到DEN/AAF大鼠肝脏ALP活性增加了79%,给予TRF后进一步增加了48%。在肝癌发生诱导过程中,谷胱甘肽S-转移酶(GST)的肝脏活性也增加了(3.5倍)。与正常对照大鼠相比,DEN/AAF起始后脂质过氧化和低密度脂蛋白(LDL)氧化增加了三倍。然而,对DEN/AAF处理的大鼠进行TRF治疗可使上述参数大幅降低(62-66%),从而限制了DEN/AAF的作用。我们得出结论,长期摄入TRF可通过其抗氧化作用预防肝脏脂质过氧化和蛋白质氧化损伤,从而降低癌症风险。